Treatment of mice with methamphetamine produces cell loss in the substantia nigra

Brain Res. 1996 Oct 28;738(1):172-5. doi: 10.1016/0006-8993(96)00995-x.

Abstract

Studies were conducted to determine if treatment of mice with methamphetamine (METH) would produce a loss of dopaminergic cells in the substantia nigra. The number of TH+/Nissl-stained was significantly decreased in both Swiss-Webster (S-W) and C57bl mice (approx. cell loss of 40% and 45%, respectively) 5-8 days after treatment with METH. In these same mice there was a corresponding decrease in neostriatal dopamine (DA) content (90% and 92%, respectively). In parallel studies, treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produced similar neuropathological effects. The finding that nigral cell loss occurs after METH treatment indicates that the METH-treated mouse may be a very relevant model of Parkinson's disease (PD).

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • Animals
  • Cell Death
  • Corpus Striatum / cytology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine / metabolism
  • Dopamine Agents / pharmacology
  • Male
  • Methamphetamine / pharmacology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred Strains
  • Substantia Nigra / cytology
  • Substantia Nigra / drug effects*
  • Substantia Nigra / metabolism
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • Dopamine Agents
  • Methamphetamine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase
  • Dopamine